Irinotecan in small-cell lung cancer: current data.
Irinotecan, a new topoisomerase I inhibitor, has significant activity in the treatment of untreated and previously treated patients with small-cell lung cancer (SCLC). In combination with cisplatin, a Japanese randomized trial showed a statistically significant survival advantage over cisplatin/etoposide in chemotherapy- naive patients with extensive-stage disease. This represents the first major advance in the treatment of extensive-stage SCLC in 20 years. Randomized trials in the United States are underway to confirm these impressive results. Meanwhile, trials incorporating irinotecan and cisplatin into treatment regimens for limited-stage disease are being conducted. Furthermore, irinotecan-containing regimens with other agents such as carboplatin, etoposide, and paclitaxel in first- or second-line therapies for SCLC are being evaluated. Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease.